SEC Form 4 · accession 0000899243-18-025318
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chandra Vargeese
Officer — Senior VP, Drug Discovery
Period of report
Sep 24, 2018
Accepted (ET)
Sep 26, 2018 · 6:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 24, 2018 | M | 3,000 | $2.48 | A | 30,300 | D | |
| Ordinary Shares | Sep 24, 2018 | S | 3,000 | $55.00 | D | 27,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $2.48 | Sep 24, 2018 | M | 3,000 | D | — | Mar 10, 2025 | Ordinary Shares | 3,000 | 149,542 | D |
Explanation of responses
- F1The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.
- F2The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.